Medigene (MDGEF) Stock Price, News & Analysis

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Key Stats

• Today's Range: $2.59 to $2.59
• 50-Day Range: $1.30 to $1.30
• 52-Week Range: $1.10 to $1.30
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDGEF Stock Analysis - Frequently Asked Questions

How have MDGEF shares performed this year?

Medigene's stock was trading at $1.2950 at the beginning of 2025. Since then, MDGEF stock has increased by 100.0% and is now trading at $2.59.
View the best growth stocks for 2025 here.

When did Medigene's stock split?

Shares of Medigene reverse split before market open on Saturday, January 1st 2000. The 1-2 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

How do I buy shares of Medigene?

Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MDGEF
• CIK: N/A
• Web: www.medigene.com
• Phone: (989) 200-0330
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A